Tcr2 Therapeutics Inc

Tcr2 Therapeutics — Corporate Update (December 2020)

21 slides from Tcr2 Therapeutics's corporate update, Dec 14, 2020

  1. Slide 1: Interim Clinical Data from Gavo-cel (TC-210) Patients

    Interim Clinical Data from Gavo-cel (TC-210) Patients December 2020 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation has been prepared by TCR2 Therapeutics Inc. (“we,” “us,” or “our”) and contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are neither

  3. Slide 3: Introduction

    Introduction Chief Executive Officer

  4. Slide 4: Key Takeaways from First Eight TC-210 Patients

    Key Takeaways from First Eight TC-210 Patients 45% Patients Eligible for TC-210 Based on Mesothelin Threshold 100% Manufacturing Success Rate Generic TC-210 Name gavocabtagene autoleucel (“gavo-cel”) New, Shorter Safety Observation Period 14 Days LD, Lymphodepletion; PR, Partial Response; ORR, Overa

  5. Slide 5: Gavo-cel Clinical Trial Review

    Gavo-cel Clinical Trial Review Chief Medical Officer

  6. Slide 6: Gavo-cel Phase 1/2 Trial in MSLN+ Solid Tumors

    Gavo-cel Phase 1/2 Trial in MSLN+ Solid Tumors RP2D Ovarian Cancer n=10 NSCLC n=8 MPM n=10 Cholangiocarcinoma n=10 NSCLC n=12 + anti-PD1 PHASE 2: Expansion Indications with potential for accelerated approval LD, Lymphodepletion; RP2D, Recommended Phase 2 dose; MPM, Malignant Pleural/Peritoneal Mesot

  7. Slide 7: Accelerated Dose Escalation Enrollment

    Accelerated Dose Escalation Enrollment Modified 3+3 Dose Escalation; 14-Day Intra-Cohort Safety Observation Periods Each Dosing Cohort Consists of: Patient 1 14 DAYS Patient 4 Patient 2 Patient 3 Next Cell Dose 14 DAYS 28 DAYS w/o LD w/ LD w/ LD LD, Lymphodepletion; RP2D, Recommended Phase 2 dose Re

  8. Slide 8: Pre-Screening, Enrollment and Manufacturing Activity

    Patients Pre-Screened 119 Tumor Samples Evaluable 87 MSLN 2+/3+ in ≥ 50% Viable Tumor Cells n (%) 39 (45) Patients Enrolled 26 Patients Apheresed 23 Patients Manufactured 17 Pre-Screening, Enrollment and Manufacturing Activity Data Cutoff – November 24, 2020

  9. Slide 9: Patient Characteristics

    Patient Characteristics Characteristics N = 8 Median age, years (range) 64.5 (36-84) Cancer diagnosis Mesothelioma 7 (5 peritoneal, 2 pleural) Ovarian cancer 1 Median No. of prior therapies (range) 5.5 (2-9) ≥4 prior therapies, No. (%) 5 (63) Prior ICI therapy, No. (%) 6 (75) Prior anti-MSLN directe

  10. Slide 10: Summary of Grade ≥3 Treatment Emergent Adverse Events

    Summary of Grade ≥3 Treatment Emergent Adverse Events Adverse Event N = 8 (%) Hematologic Neutropenia 6 (75) Lymphopenia 7 (88) Thrombocytopenia 2 (25) Adverse Events of Special Interest On Target / On Tumor CRS 2 (25) Neurotoxicity 0 On Target / Off Tumor Pericarditis / Pericardial effusion 0 Pleur

  11. Slide 11: RECIST v1.1 Response Assessment Summary

    RECIST v1.1 Response Assessment Summary Dose Level 0 1 1 1 1 1 1 2 Patients 1 2 3 4 5 6 7 8 Age/Sex 61/M 74/M 52/F 36/M 70/F 69/M 84/F 46/M Diagnosis MPM MPM MPM MPM Ovarian Ca MPM MPM MPM MSLN 2+/3+ (% of tumor cells) 90 60 73 95 55 90 100 90 No. Prior Rx 8 3 3 9 6 5 2 9 Prior ICI Yes Yes No Yes No

  12. Slide 12: Tumor Regression Observed in All Patients with Gavo-cel

    Tumor Regression Observed in All Patients with Gavo-cel Change in Target Lesions from Baseline (%) DL0 (5x107 cells/m2, no LD) DL1 (5x107 cells/m2, + LD) DL2 (1x108 cells/m2, no LD) Patients LD, Lymphodepletion Patients All Gavo-cel + LD Number 8 6 ORR 38% 50% DCR 100% 100% Data Cutoff – November 24

  13. Slide 13: Early Efficacy Case Study: Patient 5

    Partial Response (RECIST v1.1), Tumor Regression (61%) 70-year-old female, High grade, Stage IV serous ovarian cancer TP53R248Q, CCNE1 amplified, wild type BRCA1/2 Failed 6 prior lines of therapy Platinum resistant Enrolled in Gavo-cel Clinical Trial Study April 2020: Lymphodepletion with Flu/Cy fol

  14. Slide 14: Patient Response and Follow-Up

    Patient Response and Follow-Up Overall Response Rate 38%, Disease Control Rate 100% Alive No LD No LD LD LD LD LD LD LD Data Cutoff – November 24, 2020 PR SD

  15. Slide 15: Gavo-cel Expansion in Peripheral Blood by qPCR

    Expansion observed in all patients Peak expansion occurred between days 7-23 post infusion Peak expansion higher with lymphodepletion Expansion Kinetics Peak Expansion Data Cutoff – November 24, 2020 Gavo-cel Expansion in Peripheral Blood by qPCR

  16. Slide 16: Increased Plasma Cytokines Following Gavo-cel Infusion

    Plasma cytokine levels increased in all patients Higher levels were observed in patients 2 and 7 (grade 3 CRS) Peak Levels IFN-g IL-10 IL-6 IL-8 TNF-a Data Cutoff – November 24, 2020 Increased Plasma Cytokines Following Gavo-cel Infusion

  17. Slide 17: Potential Correlation Between Soluble Biomarkers & Response

    Potential Correlation Between Soluble Biomarkers & Response Responders Stable Disease Disease Response Biomarkers: SMRP: soluble mesothelin related peptide MPF: megakaryocyte potentiating factor Data Cutoff – November 24, 2020 Patient 2 Patient 4 Patient 1 Patient 3 Patient 6 Patient 7

  18. Slide 18: Summary and Next Steps

    Summary and Next Steps Key Clinical Findings Tumor regression observed in every patient RECIST PR in ovarian cancer Manageable safety profile High rate of patient eligibility and 100% manufacturing success Accelerated dose escalation with new 14-day safety observation period in Phase 1 Identificatio

  19. Slide 19: Mesothelin Solid Tumors Represent A Significant Market

    Mesothelin Solid Tumors Represent A Significant Market Percent of Patients with Mesothelin Surface Expression Refs: Inaguma 2017, SEER Statistics, Morello 2016, Tozbikian 2014 Initial Gavo-cel Indications Population: 80,000 patients Expansion Opportunities Population: 159,000 patients 76% Malignant

  20. Slide 20: Clinical Corporate Milestones

    Clinical Corporate Milestones Present Initial Phase 1 Data for Gavo-cel 2020 Present Interim Phase 1 Update for Gavo-cel 2020 Present Interim Phase 1 Data for Gavo-cel at Medical Meetings 1H21 Announcement of RP2D for Gavo-cel 2021 Initiation of Phase 2 Expansion for Gavo-cel 2021 Present Initial Ph

  21. Slide 21: Thank You

    POWERING THE TCR TO TRANSFORM THE LIVES OF CANCER PATIENTS WITH SOLID TUMORS Thank You

TCR2 Therapeutics — Corporate Update (December 2020) on 6ix